Galderma Group Ag · SIX:GALD
Galderma — J.P. Morgan Healthcare Conference 2026
18 slides from Galderma's conference presentation, Jan 13, 2026
Slide 1: Galderma: building a dermatology powerhouse
Galderma: building a dermatology powerhouse Flemming Ørnskov, M.D., MPH Chief Executive Officer JANUARY 13, 2026
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this Presentation are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates",
Slide 3: Transformation largely completed as we advance on our journey to build the global dermatology powerhouse
Transformation largely completed as we advance on our journey to build the global dermatology powerhouse 2020-2023 2024-2025 2026+ New stand-alone Capital structure reset as Diversified long-term company owned by PE newly listed, low free float shareholder base Execution Refocused on dermatologists
Slide 4: Uniquely positioned with the largest integrated dermatology platform
Uniquely positioned with the largest integrated dermatology platform Broadest portfolio with Global scale with omni-channel Market-leading leading science & innovation execution excellence education & services Broadest dermatology portfolio of Global commercial presence with notable Broad education,
Slide 5: Our unique integrated dermatology strategy has demonstrated its value creation potential
Our unique integrated dermatology strategy has demonstrated its value creation potential as we enter growth inflection New stand-alone Capital structure reset as Diversified long-term company owned by PE newly listed, low free float focused shareholders 2019 2024 2026-2027 Net sales in USD 2.7 B 4.4
Slide 6: 2026: Expanding opportunities to drive growth
2026: Expanding opportunities to drive growth 1 Ramping-up significant launches 2025-26 includes Nemluvio, Relfydess, Sculptra (China), Restylane SHAYPE (Brazil), new Restylane indications (U.S.), and Dermatological Skincare ongoing innovation 5 Dynamic approach 2 Global opportunity for further mark
Slide 7: Injectable Aesthetics: New launches & geographic expansion to keep contributing to outperformance
Injectable Aesthetics: New launches & geographic expansion to keep contributing to outperformance Relfydess in International markets Sculptra in China 1 year celebration in the market, now in 17 markets High satisfaction of healthcare professionals & patients Perception & satisfaction of Rapid marke
Slide 8: Injectable Aesthetics: Growing engagement on medication driven weight-loss, in a soft filler market
Injectable Aesthetics: Growing engagement on medication driven weight-loss, in a soft filler market U.S. ‘Sculpt & Lift’ direct-to-consumer campaign launched in October 2025 >450 M media impressions 2,500 healthcare professionals reached through education & training "The solution can be found in you
Slide 9: Injectable Aesthetics: Preparing the next frontier into (peri)menopause
Injectable Aesthetics: Preparing the next frontier, by leading the aesthetics market expansion into (peri)menopause 47 million new entrants per year and >1.2 billion women by 2030 A growing underserved Galderma 2025 market research showed a high unmet need in knowledge about menopause: population wi
Slide 10: Dermatological Skincare: Exiting 2025 with strong growth momentum – Cetaphil 11.11 in China
Dermatological Skincare: Exiting 2025 with a strong growth momentum – Another record Cetaphil 11.11 season in China Strong activation elevating brand power Outstanding growth outperforming the skincare market >3 million >10 billion E-commerce YoY growth, Cetaphil vs. total skincare by platform e-com
Slide 11: Dermatological Skincare: Multiple portfolio expansion opportunities Internationally
Dermatological Skincare: Multiple portfolio expansion opportunities Internationally, including Cetaphil Skin Activator U.S. showcase Top 10 new product introduction end of 20251 in the U.S. Hands & Body Lotion segment >1.4 B impressions since the October 2025 launch Dermatologist recommended & partn
Slide 12: Nemluvio: U.S. on a strong launch trajectory
Nemluvio: U.S. on a strong launch trajectory Before nemolizumab Paid NBRx1 weekly market share trend (new patient starts) ~39% ~9% in prurigo nodularis in atopic dermatitis Majority After 8 weeks on nemolizumab share of patients new to advanced therapies (“biologic naïve”) Percentage of patients cov
Slide 13: Nemluvio: Itch relief main reason to prescribe
Nemluvio: Itch relief main reason to prescribe, while real world experience provides conviction also on skin clearance Share of U.S healthcare professional that rate brand attributes high in moderate-to-severe atopic dermatitis Nemluvio Leading brand Prescribers familiar with Nemluvio1 Nemluvio adop
Slide 14: Focused capital allocation: Organic growth still the priority
Focused capital allocation: Organic growth still the priority, with increased strategic optionality Priorities Attractive mid-term outlook from organic growth 1. Organic Investing behind the growth momentum Group net sales ‘Low to mid-teens2’ CC 2023-2027E CAGR incl. nemolizumab growth of the curren
Slide 15: A unique investment opportunity with EPS growth above peers
A unique investment opportunity with EPS growth above peers Leading positions in Proven track record of Top-line growth potential Bottom-line expansion & attractive end markets delivery with a long run-rate strengthened balance sheet Est. mid-term market growth1 Figures in B USD Key drivers of growt
Slide 16: Significant transformation largely completed, with a unique & proven integrated dermatology strategy
Significant transformation largely completed, with a unique & proven integrated dermatology strategy From: setting up a new standalone PE-owned company To: a publicly listed company with long-term focused shareholders which is building the foundation for a dermatology powerhouse Attractive outlook w
Slide 17: GALDERMA
GALDERMA EST. 1981
Slide 18: For more information, please visit our website
For more information, please visit our website: Investors | Galderma For any questions, please reach out by email at: investors@galderma.com